The need for regulatory approval of new therapies for the treatment of Alzheimer's disease—a progressive neurodegenerative condition—has made the assessment of treatment efficacy an urgent priority ...

J.P. Shellnutt suffered a major stroke five years ago that left him partially paralyzed on his left side. He credits much of ...